TY - JOUR
T1 - Meningioma
T2 - A Review of Clinicopathological and Molecular Aspects
AU - Huntoon, Kristin
AU - Toland, Angus Martin Shaw
AU - Dahiya, Sonika
N1 - Publisher Copyright:
© Copyright © 2020 Huntoon, Toland and Dahiya.
PY - 2020/10/23
Y1 - 2020/10/23
N2 - Meningiomas are the most the common primary brain tumors in adults, representing approximately a third of all intracranial neoplasms. They classically are found to be more common in females, with the exception of higher grades that have a predilection for males, and patients of older age. Meningiomas can also be seen as a spectrum of inherited syndromes such as neurofibromatosis 2 as well as ionizing radiation. In general, the 5-year survival for a WHO grade I meningioma exceeds 80%; however, survival is greatly reduced in anaplastic meningiomas. The standard of care for meningiomas in a surgically-accessible location is gross total resection. Radiation therapy is generally saved for atypical, anaplastic, recurrent, and surgically inaccessible benign meningiomas with a total dose of ~60 Gy. However, the method of radiation, regimen and timing is still evolving and is an area of active research with ongoing clinical trials. While there are currently no good adjuvant chemotherapeutic agents available, recent advances in the genomic and epigenomic landscape of meningiomas are being explored for potential targeted therapy.
AB - Meningiomas are the most the common primary brain tumors in adults, representing approximately a third of all intracranial neoplasms. They classically are found to be more common in females, with the exception of higher grades that have a predilection for males, and patients of older age. Meningiomas can also be seen as a spectrum of inherited syndromes such as neurofibromatosis 2 as well as ionizing radiation. In general, the 5-year survival for a WHO grade I meningioma exceeds 80%; however, survival is greatly reduced in anaplastic meningiomas. The standard of care for meningiomas in a surgically-accessible location is gross total resection. Radiation therapy is generally saved for atypical, anaplastic, recurrent, and surgically inaccessible benign meningiomas with a total dose of ~60 Gy. However, the method of radiation, regimen and timing is still evolving and is an area of active research with ongoing clinical trials. While there are currently no good adjuvant chemotherapeutic agents available, recent advances in the genomic and epigenomic landscape of meningiomas are being explored for potential targeted therapy.
KW - clinical trials
KW - immunotherapy
KW - meningioma
KW - molecular diagnosis
KW - neurosurgery
KW - pathology
KW - radiation therapy
KW - targeted treatment
UR - http://www.scopus.com/inward/record.url?scp=85095600265&partnerID=8YFLogxK
U2 - 10.3389/fonc.2020.579599
DO - 10.3389/fonc.2020.579599
M3 - Review article
C2 - 33194703
AN - SCOPUS:85095600265
SN - 2234-943X
VL - 10
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 579599
ER -